As a multifactorial disease, temporomandibular disorders (TMD) require a complex therapeutic approach, being noninvasive therapies the first option for most patients. The aim of this study was to perform a systematic review to analyze the most common non-invasive therapies used for TMD management.
from wear caused by bruxism 6, 10, 16 . There are many types of OS with different indications and functions 1, 13, 17 . The most used are the stabilization splints, also known as Michigan splints. Usually made with hard acrylic, the splint is designed to provide a temporary and ideal occlusion leading to neuromuscular balance and decreasing muscle tension 1, 13, 17, 18 .
Low-level laser therapy (LLLT) -Photobiomodulation Therapy
LLLT is the application of light within the red and near infra-red wavelength range of 600-1000 nm. It is a non-ablative and non-thermal light 4, 7, 8, 19 , which has been widely used due its low cost, easy application, and short treatment time 3 . There is evidence that LLLT modulates the inflammatory process, reduces pain and edema, and increases blood circulation and extensibility of the nervous system 4 . In addition, no side effect is reported when correctly administered 20 . The clinical efficacy of TMD is controversial due to the difference in parameters, dosimetry, and assessment criteria used by studies, besides the clinical variability of TMD patients. For TMD symptoms, the commonly used wavelength is in the infrared spectrum from 780 nm to 904 nm [3] [4] [5] [6] [7] .
Therapeutic ultrasound (US)
US is the application of mechanical vibrations, known as sound energy, at increasing frequencies above 16 Hz generated by a piezoelectric effect using a frequency between 1.0 and 3.0 MHz. It is useful in fresh injuries with acute inflammation 21, 22 . The right dosimetry ensures an optimal outcome with minimum risk of adverse effects 21 . Another useful application of ultrasound is in the administration of anti-inflammatory ointments with a hand-held transducer. The energy forces the diffusion of medications through the skin to target underneath soft tissues. This method is called phonophoresis 21 .
Transcutaneous electrical nerve stimulation (TENS)
Among therapies for TMD, TENS has been proposed as a safe and noninvasive therapy with low-voltage electrical pulses. Using electrodes on the skin over the painful area, TENS can modulate the control system of endogenous pain promoting pain relief and reduction of muscular activity 6, 22, 23 . There are two theories explaining its action on pain modulation. One theory suggests that the rhythmic contractions of muscles caused by TENS increase blood and lymph circulation, resulting in the decrease of interstitial swelling and improvement of the circulation of noxious tissue metabolites, leading to muscle relaxation 22, 24 . The other theory is based on gate control, which preconizes that the electrical stimulus travels faster in afferent fibers of large diameters closing the pain gates of the spinal cord 24 .
Manual therapy (MT)
MT has been increasingly used due to the positive outcomes in some musculoskeletal and hypomobility conditions 25, 26 . In masticatory muscles, MT promotes muscular relaxation, stimulates joint proprioception, relieves pain, and improves mandibular movements 26 . The literature reports that MT is an important method that promotes the release of opioid and non-opioid substances and inhibitory neurotransmitters that act in the central nervous system. Moreover, some studies suggest that MT can decrease the EMG activity in masticatory muscles [26] [27] [28] .
Oral exercises and behavioral education (OE/BE)
Self-management (SM) or self-care includes cognitive behavioral therapies as education about negative habits and counseling, relaxation techniques, and home exercises 6 . There is poor evidence of its effectiveness due to the differences on prescription 12, 29 . Benefits of exercises include decrease in pain due to the release of endogenous non-opioid and opioid substances by stretching and strengthening masticatory muscles, increasing mobility, and tissue regeneration [4] [5] [6] 12, 29 . Stretching and relaxation exercises are first recommended when pain is present, helping patients to overcome the fear of moving the TMJ 6, 29 . However, most studies compare these exercises with other therapies, which makes it difficult to evaluate the real effectiveness of this therapy alone 25, [29] [30] [31] . While some studies indicate therapeutic exercises and BE as an essential part of treatment, others show the difficulties to define one program, since there is no established and tested gold standard for SM programs yet. In fact, previous studies present inconsistent results of therapeutic exercises and SM programs 5, 6, 32 .
Acupuncture
This millenary Chinese therapeutic method consists of placing needles into the skin for pain management. The technique uses specific acupoints and painful points. A variation of traditional acupuncture that has been widely used is dry needling, which applies needles with vigorous stimulation at trigger points [33] [34] [35] . Although several explanations are proposed, the mode of action is not fully clear. It is accepted that the needle penetration causes a micro-inflammation process improving blood circulation and neurotransmitters release, such as serotonin, encephalin, and endorphin, which prevent the propagation of painful stimuli [36] [37] [38] . In addition, acupuncture promotes muscle relaxation, reestablishing body and mind balance, with recent studies showing benefits in anxiety, depression, and insomnia 6, 36, 37 . For TMD patients, acupuncture is suggested as an adjunctive and important method with positive effects such as decreased muscle tension and pain 35 .
Pharmacological treatments
Pharmacological treatment is a common approach for orofacial pain as a monotherapy or associated with other therapies and surgical interventions. Used alone, it is considered a palliative therapy 39, 40 . The most commonly used drugs to decrease pain and inflammatory process in joints and/or muscles are myorelaxants, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, tricyclic antidepressants (TCAs), benzodiazepines, and corticosteroids 9, 39, 41 . A wide range of pharmacotherapeutic agents is available; however, there is a lack of scientific evidence and no conclusive result for any of these drugs for the TMD population 6, 10, 39, 42 .
Many clinical trials were performed with controversial results. Therefore, the main question of our review was: "Are non-invasive therapies effective to decrease pain and improve movements in TMD patients?".
METHODS

Search strategy and inclusion criteria
The bibliographical search was performed between January and August 2019. PubMed, Embase, and Scielo databases were used in two independent searches to identify relevant randomized clinical trials (RCTs) using non-invasive therapies in TMD patients, performed in the last 12 years. The first search used the keywords "temporomandibular disorder" OR "temporomandibular joint" AND "myofascial pain" AND "treatment". The second used the search terms "temporomandibular dysfunction" AND "pharmacologic". In addition, a hand search in the reference lists of included articles was done to identify other relevant studies and review articles.
Data collection and analysis
Two reviewers independently identified titles and abstracts resulting from the search strategy for potentially eligible studies. Duplicate items were removed as well as studies with surgical intervention, invasive therapies, and rheumatic and neurologic diseases. Afterwards, a full text reading was performed for final eligibility.
Data extraction
The data and results of each included study were extracted using a standard form. All data were crosschecked by a second reviewer. Any lack of agreement was resolved by discussion. The data analysis was based on the type of intervention and outcomes. The primary outcome of interest for this review was pain and the secondary outcome was range of motion (ROM).
Methodological quality assessment
The Cochrane risk of bias tool 43 was used to assess the methodological quality of the studies according to the following domains: random sequence generation, allocation concealment, blinding, incomplete data, selective reporting and other potential sources of bias.
RESULTS
Literature search
The initial search found 517 articles about therapies and 128 articles about pharmacological treatments, resulting in 645 articles. Of these, 557 were excluded due to duplications, invasive therapies or surgical procedures, reviews, and case reports. A total of 82 articles were selected for full text reading (63 about therapies and 25 about pharmacological treatment) and finally 35 articles were included in this systematic review ( Figure 1 ). 
Identification
Study characteristics and interventions
The main characteristics of the 35 included studies are described in Chart 1a and Chart 1b. The sample sizes ranged between 12 and 104 individuals with TMD symptoms, including men and women allocated in the same comparison group, except three studies that included only women 4, 44, 45 58 , one (3%) TCAs and Gabapentin 59 , and one (3%), melatonin 45 .
Fourteen studies (40%) did not use control or placebo groups for comparison with the test therapy. The comparison of techniques using 2 or more groups was done in 30 (86%) studies 2,5,10,24,33,44,45,54-59,61-63 .
Risk of bias is shown in Chart 2. A total of 29 (82%) studies presented low risk 1, 2, 5, 10, 15, 16, 20, 24, 25, 27, 31, 33, 36, [45] [46] [47] [48] 50, 51, [54] [55] [56] [57] [58] [59] [61] [62] [63] [64] and three (9%) presented high risk 44, 49, 61 . Other three (9%) studies showed an unclear risk of bias due to insufficient information in at least one domain 22, 52, 53 . 
Outcomes
To assess the presence of TMD, as well as the type of disorder and diagnosis of myofascial pain, 24 (68%) studies applied the standardized evaluation protocol, the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/ TMD) 1 49, 53, 54 , and two (6%) applied the Fonseca questionnaire 44, 63 . The remaining 8 (23%) studies adopted non-standard evaluation protocols, using clinical evaluation to include patients with signs and symptoms of TMD 24, 25, 33, 36, 51, 52, 55, 57 .
All studies evaluated the outcomes at baseline and after the treatment protocol 61 , with number of sessions varying from 1 week to 1 year. Pain levels were assessed as the primary outcome in all studies using Visual Analogic Scale (VAS) in 29 (83%) studies 1, 2, 10, 15, 16, 22, 24, 25, 31, 33, 36, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [61] [62] [63] [64] or an algometer to evaluate the pressure pain threshold in 5 (14%) studies 2, 36, 46, 58, 62 ; one study (3%) used the Verbal Pain Scale 59 . The results of an intragroup analysis demonstrated that 27 (77%) 5, 10, 20, 22, 24, 25, 27, 31, 33, 36, 44, 45, 46, 47, 50, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] of the studies presented reduction in pain and 22 (62%) 2, 5, 10, 15, 20, 24, 25, 31, 36, [44] [45] [46] [47] [52] [53] [54] 56, 57, 59, 60, 62, 64 , improvement in function. Among them, LLLT (34%) 2, 515, 20, 24, 44, [55] [56] [57] [58] 63, 64 , OE/BE (28%) 5, 16, 21, 25, 27, 47, 48, 50, 51, 54 , and OS (31%) 1, 10, 16, 36, [46] [47] [48] [49] [50] [51] 53, 54 were the most used. When analyzing the differences between treatments at the end of the protocols (intergroup analysis), 20 (57%) of the studies showed no significant difference in the levels of pain 1, 2, 10, 15, 16, 24, 31, 33, 36, 44, [46] [47] [48] [49] [51] [52] [53] 59, 63, 64 .
In terms of secondary outcome measures, changes in mouth opening were evaluated in 29 (82%) studies. A millimeter ruler was used in 10 (29%) studies 15, 24, 25, 31, 33, 36, 46, 56, 57, 63 and a caliper in 4 (11%) 1, 27, 52, 58 . The remaining 6 (17%) studies did not describe the secondary outcome 10, 44, 45, 49, 53, 60 . Significant improvement in mouth opening was described only in 13 (37%) studies using LLLT (17%) 15, 20, 24, 56, 57, 64 , acupuncture (6%) 36, 62 , MT (6%) 25, 52 , TENS (3%) 24 , OMT (3%) 54 , and benzodiazepine (3%) 59 . The combination of MT and OE/BE (9%) 5, 25, 54 or LLLT and OE (3%) 5 had significantly better results than the therapies alone or placebo.
DISCUSSION
Non-invasive therapies have been recommended as first choice treatment for TMD arousing the interest of many authors who attempted to find a gold standard treatment protocol 6, 7 . Despite the wide use of these therapies in clinical practice, the efficacy of most of them in TMD is still controversial, probably due to the variety of parameters and protocols 7, 60, 65 . Our results demonstrated that non-invasive therapies presented a low positive response, found in only 43% of the studies. Among them, OS, OE/BE and LLLT were the most commonly used. LLLT was the treatment with the highest rate of improved TMD symptoms. The absence of a placebo or a control group was noteworthy. The included RCTs had good methodological quality with low risk of bias.
The correct diagnostic of TMD is complex but essential to decide treatment strategies and follow the patients. The diagnosis is usually based on validated questionnaires and clinical tests 4, 7 . The RDC/TMD is one of the most used instruments which classified the types and subtypes of TMD (axis I) and information related to psychosocial aspects (axis II) of patients 6, 8 . Our review showed that 24 (68%) 1, 2, 5, 10, 15, 16, 20, 22, 27, 31, [45] [46] [47] [48] [49] 50, 54, 56, 58, 61, 62, 64 studies used a gold standard method (RDC/TMD-axis I) to diagnose TMD, which ensures a good analysis of the effects of therapies. Only few studies applied other validated index, such as Helkimo's 49, 53, 54 and Fonseca 44, 64 , to assess the severity of TMD symptoms, but these questionnaires present some limitations and are not able to provide sufficient information to classify TMD dysfunction 44, 53, 54 . Besides that, our results showed only one study 63 that considered the psychosocial aspects and their influence on primary and secondary outcomes. TMD treatment has been considered a challenge because of its multifactorial origin, including a complex interaction among physical, behavioral, social, and psychological factors 49, 52, 60 . Based on these aspects, the analysis of the impact of treatment strategies based on the perspective of quality of life has been currently suggested. Therefore, new clinical trials involving TDM treatment should include Axis II of RDC and other questionnaires of anxiety and/or quality of life.
Pain is well known as the main symptom of TMD leading the patients to incapacity and a poor quality of life. 7 Corroborating with these, our review showed that all analyzed studies evaluated pain as the primary outcome. VAS was the most common strategy to evaluate the levels of pain in 29 (83%) studies 1,2,10,15,16,22,24,25,31,33,36,45-53,55-59,61-64. Another important outcome observed in the studies analyzed was mouth opening 2, 5, 10, 15, 20, 24, 25, 31, 36, [44] [45] [46] [47] [52] [53] [54] 56, 57, 59, 60, 62, 64 . This is an important aspect to be addressed because it can interfere with patient's daily activities such as chewing, oral hygiene, smiling and others.
Interestingly, results were observed regarding the effect of different non-invasive therapies especially evaluating pain (main outcome). Analyzing intragroup data, all therapies demonstrated positive effect to relieve pain comparing the baseline with the end of the treatment. However, the intergroup analysis (comparison among groups) does not demonstrate the same positive results. Only 15 (43%) of the 35 studies presented significant difference between groups. The LLLT presented better results in most of the studies evaluating pain (17%) 5, 20, [55] [56] [57] [58] and range of movement (17%) 2, 15, 20, 56, 57, 59 .
The interest on LLLT is increasing, since its application is easy with no reported side effects 4 . Different parameters, such as number of sessions, sites of application, and dosimetry have been described, which indicate that this is a controversial therapy 3 . Some authors believe that 8 sessions with applications twice a week promote positive effects 52, 57 . However, other authors 2, 5, 15, 56 propose 12 sessions. In addition, two authors applied the therapy using 3 20 or 4 sessions 24 during only one week, although they found inconsistent results. LLLT application points also varied among studies, being the most common the jaw, masseter, temporalis, and pterygoid muscles (intraorally) 2, 56 . Better results in pain and mobility were described using pre-established muscular points (masseter, temporalis, and pterygoid) or trigger points 2 rather than the joint points. In addition, the infrared laser provides better results in the long term (180 days) compared with red laser. However, short-term effects did not show statistical difference between red and infrared wavelengths 20 . One recent study 64 , compared different protocols of LLLT (830 nm) showing that 8J/cm 2 is more effective to improve mouth opening than 60 J/cm 2 or 105 J/cm 2 . However, all protocols of LLLT promoted pain relief.
The OS is widely recommended 49 and is one of the most used treatments in the RCTs included in the present review. However, the analysis of our results showed that its benefits in improving TMD symptoms are controversial 6,49 especially because OS had been used in combination with other therapies. Among the 12 studies that used OS 1, 10, 16, 36, [46] [47] [48] [49] [50] [51] 53, 54 , only 4 (33%) used as an individual treatment option and showed reduction in pain 36, 46, 49, 54 . The other studies compared the effects of OS with acupuncture 36, 46 , Manual therapy 55 and/or NSAIDs 10, 53 and showed improvement in pain in all different treatment groups. These results indicated that all of these treatments reduced pain and can be applied alone or in combination as good choice for TMD patients.
Another non-invasive therapy commonly used in our review was OE/BE. Like OS, OE/BE had been used in clinical trials mostly in combination with other therapies. In general, among the 10 studies included, 6 (60%) showed positive results with decrease of TMD symptoms 5, 25, 27, 50, 52, 54 . It is difficult to compare the results among studies due to the differences in exercise protocols, time of duration of the treatment that varied from 10 1,48,51 to 45 min 47 and from 2 to 3 times/day 1,31,48,51 to 2 times/week 25, 47 . Two studies used a very well-designed protocol called oral myofunctional therapy which combined BE instruction, oral, respiratory and cervical exercises with thermotherapy and self-massage. Both evidenced positive results in improvement of pain and masticatory function in OE/BE group 5, 54 .
Pharmacological treatment is frequently recommended for orofacial pain 42 ; however, we found only 6 (18%) RTCs using pharmacological treatments for TMD. Most of the existing literature evaluating pharmacologic treatments are observational clinical studies instead of RCTs 40, 59 . The selected studies evaluated the effects of benzodiazepine (16%) 59 , anti-inflammatory (33%) 10, 53 , myorelaxant drugs (16%) 44 , melatonin (16%) 45 , and TCA and gabapentin (16%) 60 . Positive improvements were found only with melatonin 45 . Besides that, significant results for pain spread were found using gabapentin 60 . These results indicated that more clinical trials studies are necessary to evaluate the impact of pharmacological treatment in TMD patients.
CONCLUSION
TMD is a complex musculoskeletal disorder with several clinical, psychological, and behavioral components, leading to a difficult standardization of protocols and treatment evaluation. In this review, non-invasive therapies were the first choice for TMD patients and all of them improve, at least partially, TMD signs and symptoms. Therefore, noninvasive treatments can provide pain relief and should be prescribed before surgical procedures. LLLT, OS, OE/BE were the most commonly used therapies. LLLT was the therapy with the higher number of studies showing positive results compared to placebo, control, or other therapies. In general, important heterogeneity in treatment protocols, diagnostic and outcomes criteria was observed indicating the necessity of new well-designed randomized controlled trials.
